



30th June, 2025

Corporate Relationship Department
M/s. BSE Limited
Mumbai 400001

The Manager - Listing
M/s. National Stock Exchange of India Ltd
Mumbai 400051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, we would like to inform you that pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Muddasaani Pulla Reddy, Executive Vice President - R & D and Mr. CH Srinivas, Senior Vice President – Demand & Supply are superannuating from the Company with effect from the closure of business hours on 30th June, 2025.

Further we bring to your notice that Mr. R. Sridhar Reddy – Senior Vice President – GCQA has resigned from the Company with effect from the closure of business hours on 30th June, 2025 (copy of Resignation letter is enclosed).

The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024 are as under:

Sl. No.	Particulars			
1	Name	Dr. Muddasaani Pulla Reddy	Mr. Ch Srinivas	Mr. R Sridhar Reddy
2	Reason for Change in Senior Management	Superannuation as Executive Vice President - R & D	Superannuation as Senior Vice President – Demand & Supply	Resigned as Senior Vice President – GCQA
3	Date of cessation	With effect from the closure of business hours on 30 th June, 2025	With effect from the closure of business hours on 30 th June, 2025	With effect from the closure of business hours on 30 th June, 2025
4	Brief profile	Not Applicable	Not Applicable	Not Applicable
5	Disclosure of relationship between Directors	Not Applicable	Not Applicable	Not Applicable

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl: as above.

From

R. Sridhar Reddy

Senior Vice President – GCQA

Natco Pharma Limited

Hyderabad

Date: April 30, 2025

To

Mr. Rajeev Nannapaneni,

Chief Executive Officer

Natco Pharma Limited

Banjara Hills,

Hyderabad

Through

Mr. Lakshminarayana A - SVP-HR

Subject: Resignation from the Position of Senior Vice President – Global Corporate Quality Assurance

Dear Sir,

I hope this message finds you well.

After careful consideration, I hereby tender my resignation from my role as Senior Vice President – Global Corporate Quality Assurance at Natco Pharma Limited. I kindly request to be relieved from my duties by **June 30, 2025**.

This decision has not been easy, as it has been a privilege to be part of Natco Pharma's remarkable journey and to contribute to its commitment to quality and excellence. I am truly grateful for the opportunities I have had to contribute to the organization's strategic objectives and quality systems, and for the support and trust extended to me throughout my tenure.

It has been an honour to work with a team of dedicated professionals committed to upholding the highest standards of quality and compliance. I remain fully committed to ensuring an orderly handover and will extend my complete cooperation during the transition period.

Thank you once again for the opportunity to serve this esteemed organization.

Warm regards,



R. Sridhar Reddy